Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces the signing of a term sheet for a strategic asset ...

NSCLC remains the leading cause of cancer-related mortality worldwide, with EGFR mutations being a critical driver in approximately 10-15% of lung adenocarcinomas in Western populations, and up to 40% ...

Clinical development for both the investigational CD47-inhibitor evorpacept and the novel EGFR-targeted antibody-drug conjugate ALX2004 remains ...

FDA approves monthly subcutaneous amivantamab plus lazertinib for EGFR-mutated advanced NSCLC, cutting clinic time and ...

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of ...

FDA approved a simplified, once-monthly dosing schedule for Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) when used in combination with Lazcluze (lazertinib) as a first-line treatment for ...

Signs Term Sheet To Acquire Two Clinical-Stage NSCLC Assets. Kairos Pharma (NYSE American: KAPA) announced it has signed a term sheet for a strategic asset acquisition from Celyn Therapeutics Inc., ...

Deep in our cells, a wide range of processes are occurring constantly. These cellular processes rely on enzymes to act as catalysts and set off a series of molecular interactions. There are still many ...

Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for subcutaneous amivantamab and hyaluronidase-lpuj as ...

Introduction of a Differentiated Bispecific Nano ADC Positioned to Compete in Major Global Oncology Markets BOSTON, MA, ...

A new study using serial liquid biopsies to track how metastatic prostate cancer evolves under treatment pressure showed that ...

A new study using serial liquid biopsies to track how metastatic prostate cancer evolves under treatment pressure showed that ...